NCT07161843View on ClinicalTrials.gov

Use of QRX-3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

500

Participants

Timeline

Start Date

August 30, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

February 1, 2027

Conditions

Acute Renal Failure (ARF)Acute Tubular Necrosis

Interventions

DRUG

QRX-3

Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo

Trial Locations (1)

77583

Neukidney Inc, Rosharon

All Listed Sponsors

lead

Ebima Clifford Okundaye

INDUSTRY

NCT07161843 - Use of QRX-3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF) | Biotech Hunter | Biotech Hunter